Skip to main content

Stephenson Brian C's Form 4 filing

BridgeBio Pharma, Inc. (BBIO) · filed Nov 18, 2022

Accession no.
0001209191-22-057984
Filed
Nov 18, 2022
Trade date
Nov 16-17, 2022
Filing delay
2 days
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 3 non-derivative transactions and 4 derivative transactions. Open-market sales total $185.0K. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Stephenson Brian CCIK 0001780030Officer (Secretary, Treasurer & CFO)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Nov 16, 2022Common StockMOption exerciseAcquired+30,467–F1–371,731Direct
Nov 16, 2022Common StockFTax withholdingDisposed−10,789$9.64−$104,005.96360,942Direct
Nov 17, 2022Common StockSSaleDisposed−19,678$9.40F4−$184,973.2341,264Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Nov 16, 2022Common StockMOption exerciseDisposed−1,710$0.00$010,259Direct
Nov 16, 2022Common StockMOption exerciseDisposed−778$0.00$07,003Direct
Nov 16, 2022Common StockMOption exerciseDisposed−24,193$0.00$0120,965Direct
Nov 16, 2022Common StockMOption exerciseDisposed−3,786$0.00$011,358Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F1

Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.

Referenced by the price of 1 transaction in Table I.

F4

Represents the weighted average sale price of the shares sold from $9.14 to $9.64 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions as reported herein.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)